

# Thomas Reinert

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9496263/publications.pdf>

Version: 2024-02-01

24  
papers

3,861  
citations

430874

18  
h-index

642732

23  
g-index

24  
all docs

24  
docs citations

24  
times ranked

6089  
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating Tumor DNA in Stage III Colorectal Cancer, beyond Minimal Residual Disease Detection, toward Assessment of Adjuvant Therapy Efficacy and Clinical Behavior of Recurrences. <i>Clinical Cancer Research</i> , 2022, 28, 507-517.	7.0	104
2	Error Characterization and Statistical Modeling Improves Circulating Tumor DNA Detection by Droplet Digital PCR. <i>Clinical Chemistry</i> , 2022, 68, 657-667.	3.2	9
3	Circulating tumor <scp>DNA</scp> for prognosis assessment and postoperative management after curativeâ€”intent resection of colorectal liver metastases. <i>International Journal of Cancer</i> , 2022, 150, 1537-1548.	5.1	22
4	Tumour-agnostic circulating tumour DNA analysis for improved recurrence surveillance after resection of colorectal liver metastases: A prospective cohort study. <i>European Journal of Cancer</i> , 2022, 163, 163-176.	2.8	33
5	Circulating tumor DNA analysis for assessment of recurrence risk, benefit of adjuvant therapy, and early relapse detection after treatment in colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11-11.	1.6	18
6	Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3540-3540.	1.6	5
7	Ageâ€”stratified reference intervals unlock the clinical potential of circulating cellâ€”free <scp>DNA</scp> as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer. <i>International Journal of Cancer</i> , 2021, 148, 1665-1675.	5.1	9
8	Plasma-only ctDNA-Guided MRD Detection in Patients with CRCâ€”Letter. <i>Clinical Cancer Research</i> , 2021, 27, 6613-6613.	7.0	0
9	The effect of surgical trauma on circulating free DNA levels in cancer patientsâ€”implications for studies of circulating tumor DNA. <i>Molecular Oncology</i> , 2020, 14, 1670-1679.	4.6	89
10	Circulating tumor DNA to detect minimal residual disease, response to adjuvant therapy, and identify patients at high risk of recurrence in patients with stage I-III CRC.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4009-4009.	1.6	10
11	Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1124.	7.1	538
12	Early Detection of Metastatic Relapse and Monitoring of Therapeutic Efficacy by Ultra-Deep Sequencing of Plasma Cell-Free DNA in Patients With Urothelial Bladder Carcinoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1547-1557.	1.6	298
13	Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 5437-5445.	7.0	232
14	Direct detection of early-stage cancers using circulating tumor DNA. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	808
15	Prognostic Impact of a 12-gene Progression Score in Nonâ€”muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study. <i>European Urology</i> , 2017, 72, 461-469.	1.9	74
16	Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>Cancer Cell</i> , 2016, 30, 27-42.	16.8	486
17	Analysis of circulating tumour DNA to monitor disease burden following colorectal cancer surgery. <i>Cut</i> , 2016, 65, 625-634.	12.1	381
18	Genomic Alterations in Liquid Biopsies from Patients with Bladder Cancer. <i>European Urology</i> , 2016, 70, 75-82.	1.9	174

#	ARTICLE	IF	CITATIONS
19	Mutational Context and Diverse Clonal Development in Early and Late Bladder Cancer. <i>Cell Reports</i> , 2014, 7, 1649-1663.	6.4	128
20	Combinations of Urinary Biomarkers for Surveillance of Patients with Incident Nonmuscle Invasive Bladder Cancer: The European FP7 UROMOL Project. <i>Journal of Urology</i> , 2013, 189, 1945-1951.	0.4	48
21	Multicenter Validation of Cyclin D1, MCM7, TRIM29, and UBE2C as Prognostic Protein Markers in Non-Muscle Invasive Bladder Cancer. <i>American Journal of Pathology</i> , 2013, 182, 339-349.	3.8	71
22	Methylation Markers for Urine-Based Detection of Bladder Cancer: The Next Generation of Urinary Markers for Diagnosis and Surveillance of Bladder Cancer. <i>Advances in Urology</i> , 2012, 2012, 1-11.	1.3	29
23	Diagnosis of Bladder Cancer Recurrence Based on Urinary Levels of EOMES, HOXA9, POU4F2, TWIST1, VIM, and ZNF154 Hypermethylation. <i>PLoS ONE</i> , 2012, 7, e46297.	2.5	112
24	Comprehensive Genome Methylation Analysis in Bladder Cancer: Identification and Validation of Novel Methylated Genes and Application of These as Urinary Tumor Markers. <i>Clinical Cancer Research</i> , 2011, 17, 5582-5592.	7.0	183